Lupus nephritis is one of the most common and most serious complications of lupus, potentially causing kidney failure if uncontrolled. An estimated one-third to one-half of lupus patients develop lupus nephritis within the first six months to three years of their lupus diagnosis. There is no cure for lupus nephritis and current treatments rely on anti-inflammatory and immunosuppressive drugs that carry the risk of serious side effects.
The Lupus Nephritis Trials Network (LNTN) facilitates the conduct of investigator-initiated projects of high promise that are unlikely to be the subject of industry-sponsored clinical trials such as those that study:
- Comparative effectiveness
- Combination therapies from different manufacturers
- Non-proprietary agents
- Patient subsets
- Long-term outcomes
Learn more about our research and our members.
We are committed to the following guiding principles:
First and foremost, excellence in the quality of all aspects of clinical trials conduct.
Broad geographic and multi-disciplinary engagement of qualified investigators from relevant clinical and research areas and representation of diverse patient populations.
Commitment to a process for selection of projects, organizational leadership, structure, and governance.
SHARED CREDIT & OPPORTUNITIES
Mechanisms to insure credit and publication opportunities for all contributors.
Advancement and leadership opportunities for early and mid-career investigators with regard to the organizational structure as well as the implementation and publication of clinical trials in order to maintain a cadre of well trained, committed investigators.
Click here to request membership.
Click here to submit a Research Proposal.